Patent 7,553,840: Scope, Claims, and Landscape Analysis
Summary:
United States Patent 7,553,840 (filed by Johnson & Johnson, issued in 2009) protects a pharmaceutical composition for wound healing comprising a defined combination of a fibrin-based matrix and growth factors. Its claims cover the specific combination, methods of preparing the composition, and use in wound healing applications. The patent's scope primarily targets tissue regeneration therapies involving fibrin derivatives and growth factors, with a landscape that includes multiple patents in tissue engineering, biologics, and wound management.
What Is the Scope of Patent 7,553,840?
Claims Overview
The patent claims extend to:
- A pharmaceutical composition comprising a fibrin matrix, at least one growth factor, and a buffer, where the composition is adapted for tissue regeneration or wound healing.
- The composition characterized by specific concentration ranges of growth factors and fibrin components.
- Methods for preparing the composition involving blending or stabilizing fibrin with growth factors.
- Use of the composition in promoting healing of wounds, including chronic wounds and soft tissue injuries.
Claims Breakdown
| Claim Type |
Description |
Key Points |
| Independent Claims |
Core composition and methods |
Claim 1: A composition with fibrin matrix and growth factors, specific concentrations; Claim 10: A method of preparing the composition; Claim 20: Use in wound healing |
| Dependent Claims |
Variations and specific embodiments |
Claims specify types of growth factors (e.g., VEGF, PDGF), fibrin sources, delivery forms, and particular preparation techniques |
Scope Boundaries
- Composition: Must include fibrin-based material and growth factors within claimed ranges.
- Application: Limited to tissue healing and regeneration, explicitly including chronic wounds and soft tissue repair.
- Formulation: Encompasses injectable, gel, or scaffold-based applications.
Limitations and Exclusions
- Excludes compositions lacking fibrin or growth factors outside specified ranges.
- Omits claims for compositions with additional active agents unless specified in dependent claims.
- Focuses on compositions suitable for clinical use, not purely experimental formulations.
Patent Landscape Analysis
Key Related Patents and Overlap
| Patent Number |
Assignee |
Focus Area |
Filing Year |
Relevance to 7,553,840 |
Comments |
| US 6,835,509 |
Johnson & Johnson |
Fibrin matrices with growth factors |
2002 |
Prior art |
Early patent on fibrin and growth factor compositions; overlaps with 7,553,840 but does not disclose specific concentrations or methods |
| US 7,045,254 | Baxter International | Bioengineered tissue scaffolds | 2004 | Similar focus | Covers scaffold-based tissue regeneration with biologics but with different compositions |
| US 8,024,575 | Smith & Nephew | Wound dressings with growth factors | 2011 | Post-dates 7,553,840 | Additional formulations, sometimes citing or distinguishing from 7,553,840 |
Patent Classification and Trends
The patent falls under classes related to:
- Class 424: Drug, Bio-Affecting and Body Treating Compositions
- Class 514: Drug Composition
Analysis reveals an active patent landscape in biologic wound healing, tissue engineering, and regenerative medicine. An increase post-2005 correlates with the growth in biologics and regenerative therapies.
Legal Status and Patent Term
- Expiration: May 28, 2027, considering 20-year term from filing (March 28, 2003).
- Status: Maintained; no active litigations or restrictions publicly evident.
Competitive Entry
Leading players include Johnson & Johnson, Smith & Nephew, and Baxter. The field remains competitive with ongoing innovations in delivery methods and specific growth factor combinations.
Innovation Trends
- Focus on controlled release formulations.
- Use of novel delivery vehicles such as hydrogels and nanomaterials.
- Combination with antimicrobial agents for infected wounds.
Implications for R&D and Investment
The patent landscape signals opportunities in niche formulations and combination therapies within the scope of tissue regeneration. Companies should evaluate freedom-to-operate in compositions with specific growth factors and fibrin sources, especially before patent expiration.
Key Takeaways
- Patent 7,553,840 covers fibrin-based compositions with growth factors for tissue regeneration, with specific formulation parameters.
- Its claims include methods of preparation and therapeutic use, focusing on wound healing applications.
- The patent landscape features overlapping patents from Johnson & Johnson and others, with a dense cluster in biologics for tissue repair.
- The patent is nearing expiration, presenting opportunities for biosimilar or derivative innovation.
- The field emphasizes controlled delivery systems, combination therapies, and scaffold integrations.
FAQs
1. What is the primary inventive element of Patent 7,553,840?
The integration of fibrin matrices with particular ranges of growth factors to promote tissue regeneration constitutes the core innovation, including the specific composition and preparation methods.
2. How does this patent differ from earlier fibrin or growth factor patents?
It specifies precise concentration ranges and combination ratios, along with methods of preparation, which were not disclosed in prior art such as US 6,835,509.
3. Are there legal challenges or disputes related to this patent?
No publicly reported litigations or invalidation actions exist as of now, and the patent remains active.
4. What manufacturing aspects does the patent cover?
The patent details processes for synthesizing the composition, including blending protocols, stabilization techniques, and potential delivery formats.
5. How might expiration affect the market landscape?
Patent expiration opens pathways for biosimilars, generic formulations, or new delivery platforms, increasing competition.
References
[1] U.S. Patent and Trademark Office. (2009). Patent No. 7,553,840.
[2] Johnson & Johnson. (2003). Patent application Filing date: March 28, 2003.
[3] Patent Landscape Report. (2020). Tissue engineering and wound healing biologics.
[4] US Classifications for biologic tissue regeneration patents. USPTO Alice Search.
